These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Identifying patients for aggressive cholesterol lowering: the risk curve concept. Robinson JG; Stone NJ Am J Cardiol; 2006 Nov; 98(10):1405-8. PubMed ID: 17134640 [TBL] [Abstract][Full Text] [Related]
5. Assessing the value and affordability of cholesterol reduction in the managed care setting. Gonzalez ER; Kannewurf BS Am J Manag Care; 1998 Apr; 4(4 Suppl):S226-33; quiz S234-5. PubMed ID: 10180344 [No Abstract] [Full Text] [Related]
6. Atherosclerosis target of lipid-lowering therapy: is lower LDL cholesterol better? Jones PH Am J Manag Care; 2003 Aug; Suppl():1, 4-5. PubMed ID: 13678393 [No Abstract] [Full Text] [Related]
7. Improving cholesterol control in managed care populations. McKenney JM Am J Manag Care; 2000 Nov; 6(19 Suppl):S997-1007. PubMed ID: 11187371 [TBL] [Abstract][Full Text] [Related]
8. Critical appraisal of revised cholesterol guidelines for the very high-risk patient. Rosenson R; Lloyd-Jones D; Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):173-8. PubMed ID: 15739256 [TBL] [Abstract][Full Text] [Related]
9. Achieving cholesterol target in a managed care organization (ACTION) trial. Straka RJ; Taheri R; Cooper SL; Smith JC Pharmacotherapy; 2005 Mar; 25(3):360-71. PubMed ID: 15843283 [TBL] [Abstract][Full Text] [Related]
10. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E; Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231 [TBL] [Abstract][Full Text] [Related]
11. Impact of nonprescriptive factors on low-density lipoprotein cholesterol reduction with statins. Frolkis JP; Pearce GL; Sprecher DL Am J Cardiol; 2004 Nov; 94(10):1310-2. PubMed ID: 15541255 [TBL] [Abstract][Full Text] [Related]
12. Cholesterol: precursor to many lipid disorders. Jones PH Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815 [TBL] [Abstract][Full Text] [Related]
13. Introduction: missing the target with lipid-lowering therapy. Hunninghake DB; McKenney JM Am J Manag Care; 2000 Nov; 6(19 Suppl):S992-6. PubMed ID: 11187370 [No Abstract] [Full Text] [Related]
15. Delivering effective lipid management in the managed care setting: an interview with Leslee J. Shaw, PhD. Shaw LJ Am J Manag Care; 2002 Sep; 8(12 Suppl):S323-6. PubMed ID: 12240704 [No Abstract] [Full Text] [Related]
16. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH). McPherson R; Angus C; Murray P; Genest J; Am Heart J; 2001 Jun; 141(6):949-56. PubMed ID: 11376309 [TBL] [Abstract][Full Text] [Related]
17. Achieving target cholesterol levels in diabetic patients: potency of the statin or potency of the physician? Shani M; Dresner J; Vinker S Isr Med Assoc J; 2008 May; 10(5):354-7. PubMed ID: 18605358 [TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. Hirsch M; O'donnell J; Olsson A Int J Cardiol; 2005 Oct; 104(3):251-6. PubMed ID: 16186052 [TBL] [Abstract][Full Text] [Related]